Helix BioPharma Corp. saw a notable uptick in its stock price this week, aligning with recent corporate developments.
This week, Helix BioPharma Corp. (HBP.TO) experienced a price increase of 10.39%, closing at C$1.80, reflecting a 2.41% gain on Thursday alone. The company continues to navigate the complexities of the biotech sector amid its ongoing efforts to secure financing and advance its therapeutic programs.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeAdvertisement
Market cap
$126.79M
52W high
$5.40
52W low
$1.10
1W change
+10.39%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 47.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+47.1% Upside
Current Price
C$1.70
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
38.4%
Annualized
90-Day Vol
63.5%
Annualized
Trend (90d)
+30.7%
Annualized drift
90d Mean
C$1.90
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.76 | C$1.54 – C$2.01 |
| 60 trading days | C$1.83 | C$1.52 – C$2.21 |
| 90 trading days | C$1.90 | C$1.51 – C$2.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be aware of Helix BioPharma's current financial position and its attempts to raise capital for future projects, as well as the stock's recent performance trends.
C$1.80 closing price with a 10.39% weekly gain.
The stock's 52-week range of C$1.10 to C$5.40 indicates significant volatility, with current price levels reflecting only 16% of that range.
Bull case
The recent price increase suggests that investors are becoming more interested in Helix, likely due to optimism about the company's ongoing projects and recent announcements regarding stock options. This could be a sign of growing confidence in Helix's future prospects.
Bear case
Despite the recent price uptick, Helix BioPharma faces challenges, including a negative return on equity and a declining market cap. These factors may pose risks for investors, especially in the current tough capital markets environment.
Recent Price Action
Advertisement
Helix BioPharma Corp. has seen its stock price rise significantly, closing at C$1.80 on Thursday, reflecting a 2.41% increase for the day and a 10.39% increase over the past week. This uptick comes amidst ongoing efforts by the company to secure financing for its therapeutic programs.
Company News and Developments
While there were no major recent announcements from Helix BioPharma this week, the company has been active in its financial reporting. On June 12, 2026, it announced its financial results for the three- and nine-month periods ended April 30, 2026, emphasizing its commitment to securing necessary financing. Additionally, the company recently granted stock options to directors and employees, which may indicate a focus on incentivizing key personnel during this transitional phase.
Technical Picture
The technical landscape for HBP.TO shows a 50-day moving average of C$1.48, which is 21.9% below the current price, indicating a positive short-term trend. The 200-day moving average stands at C$1.88, showing a slight decline of 4.4% from the current close. The stock has traded within a 52-week range of C$1.10 to C$5.40, currently sitting at approximately 16% of that range. With a beta of -0.35, the stock demonstrates lower volatility compared to the broader market, which could be appealing to conservative investors.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
